Decibel Therapeutics (NASDAQ:DBTX) Lowered to Neutral at Robert W Baird wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws.
Shares of Decibel Therapeutics, Inc. (DBTX) are up 78% on Wednesday after Regeneron Pharmaceuticals agreed to acquire Decibel at $4.00 per share, with an additional non-tradeable contingent value right (CVR) of $3.